Back

Evaluating subcutaneous implantable cardioverter defibrillators in hypertrophic cardiomyopathy: fewer complications without increased therapies

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Implantable cardioverter-defibrillator therapy Implantable Cardioverter-Defibrillator (ICD) EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mr Christopher Monkhouse

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Comparison of newly detected atrial high-rate episodes incidence in single-lead ICDs with a floating atrial dipole and dual-chamber ICDs: a propensity score-matched analysis from the HMEA project
Doctor G. Mitacchione (Brescia, IT)
Abstract Slides Video
Presentation thumbnail
Single- versus dual-chamber ICD discriminators for tachyarrhythmia detection: a remote monitoring based, single-center study
Doctor F. Gausz (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Implantable cardioverter-defibrillator therapies in primary prevention are not decreased in a contemporary cohort: insights from long-term follow-up
Doctor I. Ferreira Neves (Lisboa, PT)
Abstract Slides Video
Presentation thumbnail
In silico modeling of cardiac defibrillation with novel deep septal ICD leads
Doctor G. Imnadze (Bad Oeynhausen, DE)
Abstract Slides Video
Presentation thumbnail
First real-world assessment of the extravascular implantable cardioverter-defibrillator: periprocedural outcomes from the Enlighten post-market study and comparison to a pre-market cohort
Professor L. Boersma (Nieuwegein, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Implantable cardioverter-defibrillator therapy

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Session
Recent advances in implantable cardioverter defibrillator therapy
thumbnail
Congress Presentation
My patient has an indication for ICD therapy: S-ICD should be first line therapy in all my patients
thumbnail
Congress Presentation
Transforming transvenous into substernal therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources